Prevalence of monoclonal gammopathy of undetermined significance in Thailand

International Journal of Hematology

Volumn 95, Issue 2, 2012, Pages 176-181

  Watanaboonyongcharoen, Phandee ^a   Na Nakorn, Thanyaphong ^b   Rojnuckarin, Ponlapat ^b   Lawasut, Panisinee ^a   Intragumtornchai, Tanin ^b  

^a KING CHULALONGKORN MEMORIAL HOSPITAL   (Thailand)

^b CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

Asian; M protein; Monoclonal gammopathy of undetermined significance; Prevalence

Indexed keywords

BETA GLOBULIN; IMMUNOGLOBULIN; GLYCOPROTEIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOGLOBULIN LAMBDA CHAIN; PROTEIN M (GLYCOPROTEIN);

ADULT; AGED; ARTICLE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOCLONAL IMMUNOGLOBULINEMIA; PATHOGENESIS; PREVALENCE; PROTEIN ELECTROPHORESIS; RISK FACTOR; THAILAND; ASIAN; BLOOD; ETHNOLOGY; METABOLISM; MIDDLE AGED; MULTIPLE MYELOMA; STATISTICS;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BETA-GLOBULINS; FEMALE; GAMMA-GLOBULINS; GLYCOPROTEINS; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN KAPPA-CHAINS; IMMUNOGLOBULIN LAMBDA-CHAINS; MALE; MIDDLE AGED; MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE; MULTIPLE MYELOMA; PREVALENCE; RISK FACTORS; THAILAND;

EID: 84862698736     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-011-0995-4     Document Type: Article

References (21)

1. Kyle RA, Rajkumar SV. Epidemiology of the plasma-cell disorders. Best Pract Res Clin Haematol. 2007;20:637-64. (Pubitemid 350215374)
2. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121:749-57.
3. Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002;346:564-9. (Pubitemid 34438817)
4. Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Offord JR, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med. 2006;354:1362-9.
5. Landgren O, Gridley G, Turesson I, Caporaso NE, Goldin LR, Baris D, et al. Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States. Blood.2006;107:904-6. (Pubitemid 43156286)
6. Landgren O, Katzmann JA, Hsing AW, Pfeiffer RM, Kyle RA, Yeboah ED, et al. Prevalence of monoclonal gammopathy of undetermined significance among men in Ghana. Mayo Clin Proc. 2007;82:1468-73. (Pubitemid 350211693)
7. Iwanaga M, Tagawa M, Tsukasaki K, Kamihira S, Tomonaga M. Prevalence of monoclonal gammopathy of undetermined significance: study of 52, 802 persons in Nagasaki City. Japan Mayo Clin Proc. 2007;82:1474-9. (Pubitemid 350211694)
8. Lee LN, Jan IS, Tien HF, Lin JS, Lo SC, Cheng WC. Laboratory and clinical characterization of monoclonal gammopathy in Taiwanese. J Formos Med Assoc. 2002;101:91-7.
9. Munshi NC. Monoclonal gammopathy of undetermined significance: genetic vs environmental etiologies. Mayo Clin Proc. 2007;82:1457-9. (Pubitemid 350211690)
10. Iwanaga M, Tagawa M, Tsukasaki K, Matsuo T, Yokota K, Miyazaki Y, et al. Relationship between monoclonal gammopathy of undetermined significance and radiation exposure in Nagasaki atomic bomb survivors. Blood. 2009;113:1639-50.
11. Malik AA, Ganti AK, Potti A, Levitt R, Hanley JF. Role of Helicobacter pylori infection in the incidence and clinical course of monoclonal gammopathy of undetermined significance. Am J Gastroenterol. 2002;97:1371-4. (Pubitemid 34664779)
12. Katzmann JA, Clark RJ, Abraham RS, Bryant S, Lymp JF, Bradwell AR, Kyle RA. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem. 2002;48:1437-44. (Pubitemid 34925779)
13. Saleun JP, Vicariot M, Deroff P, Morin JF. Monoclonal gammopathies in the adult population of Finistère, France. J Clin Pathol. 1982;35:63-8. (Pubitemid 12180852)
14. Ogmundsdóttir HM, Haraldsdóttir V, Jóhannesson M G, Olafsdo ́ttir G, Bjarnadóttir K, Sigvaldason H, et al. Monoclonal gammopathy in Iceland: a population-based registry and followup. Br J Haematol. 2002;118:166-73. (Pubitemid 34779533)
15. Landgren O, Weiss BM. Patterns of monoclonal gammopathy of undetermined significance and multiple myeloma in various ethnic/racial groups: support for genetic factors in pathogenesis. Leukemia. 2009;23:1691-7.
16. Cohen HJ, Crawford J, Rao MK, Pieper CF, Currie MS. Racial differences in the prevalence of monoclonal gammopathy in a community-based sample of the elderly. Am J Med 1998;104:439-44 [published correction appears in Am J Med. 1998;105(4):362]. (Pubitemid 28274847)
17. Demographics of Thailand. http://en.wikipedia.org/wiki/Demographics-of- Thailand.
18. Lee JH, Lee DS, Lee JJ, Chang YH, Jin JY, Jo DY, et al. Multiple myeloma in Korea: past, present, and future perspectives Experience of the Korean Multiple Myeloma Working Party. Int J Hematol. 2010;92:52-7.
19. Rajkumar SV, Kyle RA, Therneau TM, Melton LJ 3rd, Bradwell AR, Clark RJ, et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood. 2005;106:812-7. (Pubitemid 41076419)
20. Pasqualetti P, Collacciani A, Casale R. Risk of monoclonal gammopathy of undetermined significance: a case-referent study. Am J Hematol. 1996;52:217-20. (Pubitemid 26254861)
21. Landgren O, Kyle RA, Hoppin JA, Beane Freeman LE, Cerhan JR, Katzmann JA, et al. Pesticide exposure and risk of monoclonal gammopathy of undetermined significance in the Agricultural Health Study. Blood. 2009;113:6386-91.